Acute Kidney Injury News and Research

RSS

Acute kidney injury (AKI) involves sudden damage to the kidneys or decrease in renal function that occurs over a few hours or days. The severity of the condition can vary from a minor loss of kidney function to kidney failure.

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

CytoSorbents Corporation, a leader in critical care immunotherapy commercializing its CytoSorb extracorporeal cytokine adsorber to control deadly inflammation using blood purification, today announced an exclusive multi-year distribution agreement with Hoang Long Pharma, a medical distributor in Vietnam specializing in the distribution of innovative pharmaceuticals, biologics, and devices to treat patients suffering from critical illnesses, immunologic disorders and deficiencies, and infections.

15 Dec 2015

RPCI-led researchers identify strategies to prevent acute kidney injury

Acute kidney injury (AKI), also known as acute renal failure, is one of the main contributors to death and disability worldwide, yet no preventive treatment for the condition has been established. In a new study published in the journal Cell Death and Differentiation, a team of researchers led by scientists from Roswell Park Cancer Institute reports that they have identified 10 genes whose inhibition appears to protect kidney cells.

25 Nov 2015

Intensive management of high blood pressure reduces rates of cardiovascular disease, lowers risk of death

Jackson T. Wright Jr., MD, PhD, and researchers from University Hospitals Case Medical Center presented new results from the Systolic Blood Pressure Intervention Trial (SPRINT) showing that in patients at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of fatal and non-fatal major events or death compared to targeting systolic blood pressure to the usually recommended target of less than 140 mm Hg.

10 Nov 2015

Astute Medical, Fosun Long-March sign distribution agreement for NephroCheck Test on the Astute140 Meter

Astute Medical, Inc. today announced the signing of an agreement with Shanghai Fosun Long March Medicine Science Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., for distribution of Astute's NephroCheck Test on the Astute140 Meter in China. In addition to its planned launch of the NephroCheck Test in China, FOSUNPHARMA invested $20 million in Astute.

12 Oct 2015

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future.

3 Sep 2015

Researchers use iPSCs to explore new treatments for kidney disease

One promising way to treat diseased or damaged kidneys is cell therapies that include the transplantation of renal progenitor cells, which can then develop into the cells needed for full recovery. Acquiring a sufficient number of progenitor cells has been difficult, however, which is why scientists have considered induced pluripotent stem cells (iPSCs), since they can be expanded at significantly high levels and then differentiated into the progenitors.

22 Jul 2015

Epsom and St Helier Hospitals extend use of VitalPAC.

Since August last year nurses on Medical wards at have been recording patient observation data on mobile electronic devices such as iPods using a digital solution called VitalPAC Nurse...

4 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

An intervention known as remote ischemic preconditioning (RIPC) significantly reduced the occurrence of acute kidney injury (AKI) in cardiac surgery patients and confirmed that post-operative elevations of two kidney biomarkers act as an alarm for risk of AKI, according to a study published online today in the Journal of the American Medical Association.

30 May 2015

Kidney function plays critical role in sepsis patients

Researchers at Duke Medicine have determined that kidney function plays a critical role in the fate of patients being treated for sepsis, a potentially life-threatening complication of an infection.

21 May 2015

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

Physicians treating hospitalized patients for conditions unrelated to the kidneys should pay close attention to common blood and urine tests for kidney function in order to prevent incidental injury to the organs that help cleanse the body of toxins, new Johns Hopkins Bloomberg School of Public Health-led research suggests.

12 May 2015

Six winners share £2 million to develop cutting-edge technology to prevent kidney disease

SIX winners, announced today, will receive a share of over £2 million as part of a Small Business Research Initiative competition aimed at developing cutting-edge technology solutions to help kidney patients.

31 Mar 2015

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.

30 Mar 2015

Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Cardiovascular researchers at The Ohio State University Wexner Medical Center have shown that a protein known as MG53 is not only present in kidney cells, but necessary for the organ to repair itself after acute injury. Results from this animal model study are published in the journal Science Translational Medicine.

19 Mar 2015

Novel device improves in-hospital safety outcomes, cognitive scores at discharge

An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.

18 Mar 2015

Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI.

17 Mar 2015

Acute Kidney Injury News and Research

Further Reading

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

RPCI-led researchers identify strategies to prevent acute kidney injury

Intensive management of high blood pressure reduces rates of cardiovascular disease, lowers risk of death

Astute Medical, Fosun Long-March sign distribution agreement for NephroCheck Test on the Astute140 Meter

FDA awards research grants to boost product development for patients with rare diseases

TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

Researchers use iPSCs to explore new treatments for kidney disease

Epsom and St Helier Hospitals extend use of VitalPAC.

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Kidney function plays critical role in sepsis patients

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

Six winners share £2 million to develop cutting-edge technology to prevent kidney disease

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Novel device improves in-hospital safety outcomes, cognitive scores at discharge

Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News